Tukysa Tablet
Product Images NDC 51144-001

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tukysa (NDC 51144-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seagen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mglabel

TUKYSA 150 mg tablets label showing tucatinib as the active ingredient. The label displays the NDC 51144-002-60, indicates prescription only, and includes storage instructions to keep tablets at controlled room temperature (20°C to 25°C). It contains 60 tablets and is labelled by Seagen Inc. The label also warns to discard unused tablets 3 months after opening.*

FDA Label Image

2022 03 12

The image shows a label for TUKYSA (tucatinib) tablets 150 mg by Seagen Inc. It includes storage instructions, a warning to keep out of children, and disposal directions. The label also states the package contains 120 tablets and provides manufacturer details and barcode information.*

FDA Label Image

50mglabel

TUKYSA (tucatinib) 50 mg tablets label from Seagen Inc. The label includes dosage form as tablets, strength 50 mg, and instructions to store at controlled room temperature. It contains 60 tablets and cautions to discard unused tablets three months after opening. The label also displays the NDC 51144-001-60 and a barcode.*

FDA Label Image

Figure 1 (Fig1)

A Kaplan-Meier curve depicting progression-free survival (PFS) percentage over months since randomization for two treatment groups in the HER2CLIMB study: Tukysa plus Tras plus Cape, and Pbo plus Tras plus Cape. The graph shows PFS decreasing over time with Tukysa combination demonstrating higher survival rates compared to placebo combination. A risk table shows the number of patients remaining at risk for each group at various time points.*

FDA Label Image

Figure 2 (Fig2)

Kaplan-Meier curve showing overall survival (%) over months since randomization in the HER2CLIMB study. Two groups are compared: Tukysa plus Tras plus Cape, and placebo plus Tras plus Cape. The graph indicates survival trends up to 36 months with number at risk tables below for each treatment group at various time points.*

FDA Label Image

Logo (Logo)

FDA Label Image

Smalllogo

TUKYSA 150 mg oral tablets blister pack. The packaging features rows of circular tablets in a foil blister, labeled with TUKYSA and strength information. The labeler is SEAGEN INC. The design presents an organized arrangement of tablets for prescription use.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of tucatinib, the active ingredient in TUKYSA, shown as a molecular diagram depicting its atomic connectivity and ring structures.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.